Skip to main content

Deep Profiling of the Immune System of Multiple Myeloma Patients Using Cytometry by Time-of-Flight (CyTOF)

Part of the Methods in Molecular Biology book series (MIMB,volume 1792)

Abstract

Mass cytometry has emerged as a new state-of-the-art technology that enables in-depth characterization of cellular populations and functions at a single cell resolution. We describe the application of this technology to deeply phenotype the blood and bone marrow components of multiple myeloma patients in a clinical setting. This technology allows for simultaneous quantification of more than 40 markers, overcoming the challenges of traditional fluorescence-based flow cytometry.

Key words

  • Mass cytometry
  • CyTOF
  • Multiple myeloma
  • Immunophenotyping
  • Single cell
  • Barcoding
  • Smart tube
  • Peripheral blood
  • Bone marrow

This is a preview of subscription content, access via your institution.

Buying options

Protocol
USD   49.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4939-7865-6_4
  • Chapter length: 8 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-1-4939-7865-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   149.99
Price excludes VAT (USA)
Hardcover Book
USD   219.99
Price excludes VAT (USA)
Fig. 1

Springer Nature is developing a new tool to find and evaluate Protocols. Learn more

Change history

  • 07 February 2019

    In Chapter 4, the author’s name Homer Adams III has been modified to Adams HC 3rd, as requested by him.

References

  1. Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK (2012) A deep profiler’s guide to cytometry. Trends Immunol 33(7):323–332. https://doi.org/10.1016/j.it.2012.02.010

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  2. Spitzer MH, Nolan GP (2016) Mass Cytometry: single cells, many features. Cell 165(4):780–791. https://doi.org/10.1016/j.cell.2016.04.019

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  3. Lokhorst HM, Plesner T, Laubach JP, Nahi H, Gimsing P, Hansson M, Minnema MC, Lassen U, Krejcik J, Palumbo A, van de Donk NW, Ahmadi T, Khan I, Uhlar CM, Wang J, Sasser AK, Losic N, Lisby S, Basse L, Brun N, Richardson PG (2015) Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med 373(13):1207–1219. https://doi.org/10.1056/NEJMoa1506348

    CAS  CrossRef  PubMed  Google Scholar 

  4. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387(10027):1551–1560. https://doi.org/10.1016/S0140-6736(15)01120-4

    CAS  CrossRef  PubMed  Google Scholar 

  5. Plesner T, Arkenau HT, Gimsing P, Krejcik J, Lemech C, Minnema MC, Lassen U, Laubach JP, Palumbo A, Lisby S, Basse L, Wang J, Sasser AK, Guckert ME, de Boer C, Khokhar NZ, Yeh H, Clemens PL, Ahmadi T, Lokhorst HM, Richardson PG (2016) Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood 128(14):1821–1828. https://doi.org/10.1182/blood-2016-07-726729

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  6. Adams H, Stevenaert F, Krejcik J, Van der Borght K, Casneuf T, Smets T, Bald J, Abraham Y, Ceulemans H, Vanhoof G, Ahmadi T, Usmani SZ, Plesner T, Lonial S, van Kessel-Welmers B, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK (2016) High-parameter mass cytometry (CyTOF) evaluation of relapsed/refractory multiple myeloma (MM) Pts (Pts) treated with daratumumab supports immune modulation as a novel mechanism of action. Blood 128(22):4521

    CrossRef  Google Scholar 

  7. Qiu P, Simonds EF, Bendall SC, Gibbs KD Jr, Bruggner RV, Linderman MD, Sachs K, Nolan GP, Plevritis SK (2011) Extracting a cellular hierarchy from high-dimensional cytometry data with SPADE. Nat Biotechnol 29(10):886–891. https://doi.org/10.1038/nbt.1991

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Christoph Heuck for his suggestions and critical reading of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Greet Vanhoof .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Verify currency and authenticity via CrossMark

Cite this protocol

Smets, T., Stevenaert, F., Adams, H., Vanhoof, G. (2018). Deep Profiling of the Immune System of Multiple Myeloma Patients Using Cytometry by Time-of-Flight (CyTOF). In: Heuck, C., Weinhold, N. (eds) Multiple Myeloma. Methods in Molecular Biology, vol 1792. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-7865-6_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-7865-6_4

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-4939-7864-9

  • Online ISBN: 978-1-4939-7865-6

  • eBook Packages: Springer Protocols